{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T16:13:39Z","timestamp":1655396019196},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00104-008-1617-4","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T15:50:27Z","timestamp":1239033027000},"page":"281-293","source":"Crossref","is-referenced-by-count":9,"title":["Therapie beim lokal fortgeschrittenen Rektumkarzinom"],"prefix":"10.1007","volume":"80","author":[{"given":"T.","family":"Liersch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,8]]},"reference":[{"key":"1617_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","volume":"8","author":"Altieri","year":"2008","unstructured":"Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61\u201370","journal-title":"Nat Rev Cancer"},{"key":"1617_CR2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.2004.05.166","volume":"22","author":"Ayers","year":"2004","unstructured":"Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant pacliaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284\u20132293","journal-title":"J Clin Oncol"},{"key":"1617_CR3","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/sj.onc.1210506","volume":"26","author":"Bostner","year":"2007","unstructured":"Bostner J, Ahnstrom Walterson M, Fornander T et al (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997\u20137005","journal-title":"Oncogene"},{"key":"1617_CR4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2007.12.019","volume":"72","author":"Capirci","year":"2008","unstructured":"Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99\u2013107","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1617_CR5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","volume":"362","author":"Chang","year":"2003","unstructured":"Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362\u2013369","journal-title":"Lancet"},{"key":"1617_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/SLA.0b013e31816bcd49","volume":"247","author":"Croner","year":"2008","unstructured":"Croner RS, F\u00f6rtsch T, Br\u00fcckl WM et al (2008) Molecular signature for lymphatic metastasis in colorectal carcinomas. Ann Surg 247:803\u2013810","journal-title":"Ann Surg"},{"key":"1617_CR7","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1200\/JCO.2008.18.3160","volume":"26","author":"De","year":"2008","unstructured":"De Vries, de Jong S (2008) Eploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol 26:5151\u20135153","journal-title":"J Clin Oncol"},{"key":"1617_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00066-008-1751-4","volume":"184","author":"Dunst","year":"2008","unstructured":"Dunst J, Debus J, Rudat V et al (2008) Neoadjuvant Capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer. Mature results of a phase II trial. Strahlenther Onkol 184:450\u2013456","journal-title":"Strahlenther Onkol"},{"key":"1617_CR9","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2002.02.049","volume":"20","author":"Dunst","year":"2002","unstructured":"Dunst J, Reese T, Sutter T et al (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983\u20133991","journal-title":"J Clin Oncol"},{"key":"1617_CR10","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","volume":"23","author":"Folkesson","year":"2005","unstructured":"Folkesson J, Birgisson H, Pahlmann L et al (2005) Swedish Rectal Cancer Trial. Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23:5644\u20135650","journal-title":"J Clin Oncol"},{"key":"1617_CR11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2003.10.045","volume":"21","author":"Gerard","year":"2003","unstructured":"Gerard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 21:1119\u20131124","journal-title":"J Clin Oncol"},{"key":"1617_CR12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1200\/JCO.2005.00.406","volume":"23","author":"Ghadimi","year":"2005","unstructured":"Ghadimi BM, Grade M, Difilippantonio MJ et al (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826\u20131838","journal-title":"J Clin Oncol"},{"key":"1617_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/0008-5472.CAN-05-2533","volume":"66","author":"Grade","year":"2006","unstructured":"Grade M, Ghadimi BM, Varma S et al (2006) Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt\/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66:267\u2013282","journal-title":"Cancer Res"},{"key":"1617_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/0008-5472.CAN-06-1514","volume":"67","author":"Grade","year":"2007","unstructured":"Grade M, H\u00f6rmann P, Becker S et al (2007) Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 67:41\u201356","journal-title":"Cancer Res"},{"key":"1617_CR15","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1200\/JCO.2005.09.077","volume":"23","author":"Hannemann","year":"2005","unstructured":"Hannemann J, Oosterkamp HM, Bosch CA et al (2005) Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23:3331\u20133342","journal-title":"J Clin Oncol"},{"key":"1617_CR16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/bjs.1800691019","volume":"69","author":"Heald","year":"1982","unstructured":"Heald RJ, Ryall RDH, Husband E (1982) The mesorectum in rectal cancer surgery: clue to pelvic recurrence. Br J Surg 69:613\u2013616","journal-title":"Br J Surg"},{"key":"1617_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00384-002-0468-6","volume":"18","author":"Hermanek","year":"2003","unstructured":"Hermanek P, Hermanek P, Hohenberger W et al (2003) The pathological assessment of mesorectal excision: implications for further treatment quality management. Int J Colorectal Dis 18:335\u2013341","journal-title":"Int J Colorectal Dis"},{"key":"1617_CR18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2005.04.171","volume":"23","author":"Hofheinz","year":"2005","unstructured":"Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F et al (2005) Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350\u20131357","journal-title":"J Clin Oncol"},{"key":"1617_CR19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.1663","volume":"204","author":"Jakob","year":"2004","unstructured":"Jakob C, Aust DE, Meyer W et al (2004) Thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase expression and histological tumour regression after 5-FU based neoadjuvant chemoradiotherapy in rectal cancer. J Pathol 204:562\u2013568","journal-title":"J Pathol"},{"key":"1617_CR20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/01.pas.0000170346.55304.88","volume":"29","author":"Jakob","year":"2005","unstructured":"Jakob C, Liersch T, Meyer W et al (2005) Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II\/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 29:1304\u20131309","journal-title":"Am J Surg Pathol"},{"key":"1617_CR21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable cancer. N Engl J Med 345:638\u2013646","journal-title":"N Engl J Med"},{"key":"1617_CR22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0959-8049(02)00049-7","volume":"38","author":"Kapiteijn","year":"2002","unstructured":"Kapiteijn E, van de Velde CJ (2002) Developments and quality assurance in rectal cancer surgery. Eur J Cancer 38:919\u2013936","journal-title":"Eur J Cancer"},{"key":"1617_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijrobp.2004.02.007","volume":"60","author":"Knutsen","year":"2004","unstructured":"Knutsen A, Adell G, Sun XF (2004) Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 60:149\u2013155","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1617_CR24","doi-asserted-by":"crossref","unstructured":"Liersch T, Grade M, Gaedcke J et al (2009) Preoperative chemoradiotherapy in locally advanced rectal cancer: Correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenetics, in press","DOI":"10.1016\/j.cancergencyto.2008.11.011"},{"key":"1617_CR25","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1200\/JCO.2005.04.2739","volume":"24","author":"Liersch","year":"2006","unstructured":"Liersch T, Langer C, Ghadimi BM et al (2006) Lymph node status and TS-gene expression are prognostic markers in rectal cancer UICC Stage II\/III patients after neoadjuvant 5-FU-based chemoradiotherapy. J Clin Oncol 24:4062\u20134068","journal-title":"J Clin Oncol"},{"key":"1617_CR26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1200\/JCO.2001.19.7.1976","volume":"19","author":"Marijnen","year":"2001","unstructured":"Marijnen CA, Nagtegaal ID, Kranenbarg EK et al (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976\u20131984","journal-title":"J Clin Oncol"},{"key":"1617_CR27","doi-asserted-by":"crossref","unstructured":"Morelli MP, Cascone T, Troiani T et al (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16 [Suppl 4]:61\u201368","DOI":"10.1093\/annonc\/mdi910"},{"key":"1617_CR28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","volume":"246","author":"Peeters","year":"2007","unstructured":"Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years increased local control but no survival benefit in irradiated patients with respectable rectal carcinoma. Ann Surg 246:693\u2013701","journal-title":"Ann Surg"},{"key":"1617_CR29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00000658-199802000-00001","volume":"227","author":"Porter","year":"1998","unstructured":"Porter GA, Soskolne CL, Yakimets WW, Newman SC (1998) Surgeon-related factors and outcome in rectal cancer. Ann Surg 227:157\u2013167","journal-title":"Ann Surg"},{"key":"1617_CR30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2007.07.2356","volume":"70","author":"R\u00f6del","year":"2008","unstructured":"R\u00f6del C, Arnold D, Hipp M et al (2008) Phase I\/II trial of Cetuximab, Capecitabine, Oxaliplatin and radiotherapy as preoperatuive treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081\u20131086","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1617_CR31","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/JCO.2003.02.505","volume":"21","author":"R\u00f6del","year":"2003","unstructured":"R\u00f6del C, Grabenbauer GG, Papadopoulos T et al (2003) Phase I\/II trial of capecitabine, oxaliplatin and radiation for rectal cancer. J Clin Oncol 21:3098\u20133104","journal-title":"J Clin Oncol"},{"key":"1617_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","volume":"25","author":"R\u00f6del","year":"2007","unstructured":"R\u00f6del C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110\u2013117","journal-title":"J Clin Oncol"},{"key":"1617_CR33","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","volume":"23","author":"R\u00f6del","year":"2005","unstructured":"R\u00f6del C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression grading following preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688\u20138696","journal-title":"J Clin Oncol"},{"key":"1617_CR34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijrobp.2008.02.011","volume":"71","author":"R\u00f6del","year":"2008","unstructured":"R\u00f6del F, Frey B, Leitmann W et al (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247\u2013255","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1617_CR35","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-04-3028","volume":"65","author":"R\u00f6del","year":"2005","unstructured":"R\u00f6del F, Hoffmann J, Distel L et al (2005) Survivin as a radioresistance factor and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881\u20134887","journal-title":"Cancer Res"},{"key":"1617_CR36","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2007.14.8981","volume":"26","author":"Royston","year":"2008","unstructured":"Royston P, Sauerbrei W (2008) Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol 26:1397\u20131399","journal-title":"J Clin Oncol"},{"key":"1617_CR37","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative compared with postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 351:1731\u20131740","journal-title":"N Engl J Med"},{"key":"1617_CR38","doi-asserted-by":"crossref","unstructured":"Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-Leitlinie \u201eKolorektales Karzinom\u201d 2008. [Update S3-guideline \u201eColorectal Carcinoma\u201d 2008.] Z Gastroenterol 46:799\u2013840","DOI":"10.1055\/s-2008-1027726"},{"key":"1617_CR39","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1200\/JCO.2005.02.8712","volume":"23","author":"Simon","year":"2005","unstructured":"Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332\u20137341","journal-title":"J Clin Oncol"},{"key":"1617_CR40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1740774507076800","volume":"4","author":"Simon","year":"2007","unstructured":"Simon R (2007) New challenges for 21st century clinical trials. Clin Trials 4:167\u2013177","journal-title":"Clin Trials"},{"key":"1617_CR41","doi-asserted-by":"crossref","unstructured":"Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors. Springer, Berlin","DOI":"10.1002\/0471463752"},{"key":"1617_CR42","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","volume":"26","author":"Tolcher","year":"2008","unstructured":"Tolcher AW, Mita A, Lewis LD et al (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198\u20135203","journal-title":"J Clin Oncol"},{"key":"1617_CR43","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"van","year":"2002","unstructured":"van de Vijver MJ, He YD, van\u2019t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999\u20132009","journal-title":"N Engl J Med"},{"key":"1617_CR44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"van","year":"2002","unstructured":"van\u2019t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530\u2013536","journal-title":"Nature"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-008-1617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00104-008-1617-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-008-1617-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T09:46:53Z","timestamp":1589708813000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00104-008-1617-4"}},"subtitle":["Ans\u00e4tze zur Individualisierung"],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["1617"],"URL":"https:\/\/doi.org\/10.1007\/s00104-008-1617-4","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}